| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | 0.077 | 0.03 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.082 | 0.03 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | 0.076 | 0.03 |
| mRNA | CD-1530 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.03 |
| mRNA | salermide | CTRPv2 | pan-cancer | AAC | 0.1 | 0.03 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.03 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.083 | 0.03 |
| mRNA | BRD-K99584050 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.03 |
| mRNA | serdemetan:SCH-529074 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.077 | 0.03 |
| mRNA | Ki8751 | CTRPv2 | pan-cancer | AAC | 0.078 | 0.03 |